(VEEV) Veeva Systems - Ratings and Ratios
Cloud Software, Data Management, Clinical Platform, Business Consulting, CRM
VEEV EPS (Earnings per Share)
VEEV Revenue
Description: VEEV Veeva Systems
Veeva Systems Inc Class A (NYSE:VEEV) is a cloud-based software provider catering to the life sciences industry globally, with a diverse product portfolio that includes Veeva Commercial Cloud, Veeva Data Cloud, Veeva Development Cloud, and Veeva Quality Cloud. These offerings enable pharmaceutical and biotechnology companies to manage their commercial operations, data, clinical trials, and quality management processes efficiently.
From a business perspective, VEEVs revenue growth is driven by its subscription-based model, with a high customer retention rate. Key performance indicators (KPIs) to watch include revenue growth rate, customer acquisition costs, and the ratio of sales and marketing expenses to revenue. The companys ability to expand its product offerings and penetrate new markets will be crucial to its future growth.
Analyzing VEEVs financials, we can see that the company has a strong track record of generating cash from operations, with a significant portion of its revenue being recurring in nature. Key metrics to monitor include the companys operating margin, which has been expanding due to scale and efficiency gains, and its return on equity (RoE), which is currently at 13.74%. The companys ability to invest in research and development (R&D) while maintaining a healthy balance sheet is essential to driving innovation and growth.
From a valuation perspective, VEEVs price-to-earnings (P/E) ratio is 59.49, indicating a premium valuation compared to some of its peers. However, its forward P/E ratio is lower at 38.46, suggesting that the market expects earnings growth in the future. Investors should monitor the companys ability to deliver on its growth expectations and maintain its competitive edge in the market.
To further evaluate VEEVs investment potential, its essential to analyze its competitive positioning, market share, and the overall growth prospects of the life sciences industry. The companys strong brand reputation, extensive product portfolio, and strategic partnerships are key strengths that can drive long-term success.
VEEV Stock Overview
| Market Cap in USD | 46,350m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2013-10-16 |
VEEV Stock Ratings
| Growth Rating | 58.8% |
| Fundamental | 80.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 7.70% |
| Analyst Rating | 3.88 of 5 |
VEEV Dividends
Currently no dividends paidVEEV Growth Ratios
| Growth Correlation 3m | -21.6% |
| Growth Correlation 12m | 82.1% |
| Growth Correlation 5y | -27.7% |
| CAGR 5y | 16.62% |
| CAGR/Max DD 3y | 0.62 |
| CAGR/Mean DD 3y | 2.00 |
| Sharpe Ratio 12m | -0.46 |
| Alpha | 8.01 |
| Beta | 0.724 |
| Volatility | 34.08% |
| Current Volume | 935.7k |
| Average Volume 20d | 1270.2k |
| Stop Loss | 266.3 (-3.7%) |
| Signal | -0.16 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (809.9m TTM) > 0 and > 6% of Revenue (6% = 178.1m TTM) |
| FCFTA 0.17 (>2.0%) and ΔFCFTA 1.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 193.4% (prev 167.0%; Δ 26.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 1.35b > Net Income 809.9m (YES >=105%, WARN >=100%) |
| Net Debt (-1.84b) to EBITDA (888.7m) ratio: -2.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (167.3m) change vs 12m ago 1.65% (target <= -2.0% for YES) |
| Gross Margin 75.59% (prev 73.35%; Δ 2.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.43% (prev 40.65%; Δ 0.77pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 10.10
| (A) 0.72 = (Total Current Assets 6.99b - Total Current Liabilities 1.26b) / Total Assets 8.00b |
| (B) 0.49 = Retained Earnings (Balance) 3.88b / Total Assets 8.00b |
| (C) 0.12 = EBIT TTM 868.9m / Avg Total Assets 7.17b |
| (D) 2.85 = Book Value of Equity 3.88b / Total Liabilities 1.36b |
| Total Rating: 10.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.08
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.33% = 1.67 |
| 3. FCF Margin 44.95% = 7.50 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda 0.13 = 2.49 |
| 6. ROIC - WACC 2.45% = 3.07 |
| 7. RoE 13.40% = 1.12 |
| 8. Rev. Trend 97.56% = 4.88 |
| 9. Rev. CAGR 13.85% = 1.73 |
| 10. EPS Trend 93.94% = 2.35 |
| 11. EPS CAGR 22.85% = 2.28 |
What is the price of VEEV shares?
Over the past week, the price has changed by -2.25%, over one month by +0.53%, over three months by -2.86% and over the past year by +27.37%.
Is Veeva Systems a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VEEV is around 249.49 USD . This means that VEEV is currently overvalued and has a potential downside of -9.75%.
Is VEEV a buy, sell or hold?
- Strong Buy: 12
- Buy: 7
- Hold: 11
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the VEEV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 316.7 | 14.6% |
| Analysts Target Price | 316.7 | 14.6% |
| ValueRay Target Price | 278.7 | 0.8% |
Last update: 2025-09-10 02:42
VEEV Fundamental Data Overview
CCE Cash And Equivalents = 6.40b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 58.1852
P/E Forward = 37.4532
P/S = 15.6154
P/B = 6.9819
P/EG = 1.4717
Beta = 0.951
Revenue TTM = 2.97b USD
EBIT TTM = 868.9m USD
EBITDA TTM = 888.7m USD
Long Term Debt = 105.8m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 10.7m USD (from shortTermDebt, last quarter)
Debt = 116.5m USD (Calculated: Short Term 10.7m + Long Term 105.8m)
Net Debt = -1.84b USD (from netDebt column, last quarter)
Enterprise Value = 40.06b USD (46.35b + Debt 116.5m - CCE 6.40b)
Interest Coverage Ratio = unknown (Ebit TTM 868.9m / Interest Expense TTM 0.0)
FCF Yield = 3.33% (FCF TTM 1.33b / Enterprise Value 40.06b)
FCF Margin = 44.95% (FCF TTM 1.33b / Revenue TTM 2.97b)
Net Margin = 27.29% (Net Income TTM 809.9m / Revenue TTM 2.97b)
Gross Margin = 75.59% ((Revenue TTM 2.97b - Cost of Revenue TTM 724.5m) / Revenue TTM)
Tobins Q-Ratio = 10.32 (Enterprise Value 40.06b / Book Value Of Equity 3.88b)
Interest Expense / Debt = 25.96% (Interest Expense 30.2m / Debt 116.5m)
Taxrate = 22.32% (205.2m / 919.4m)
NOPAT = 674.9m (EBIT 868.9m * (1 - 22.32%))
Current Ratio = 5.57 (Total Current Assets 6.99b / Total Current Liabilities 1.26b)
Debt / Equity = 0.02 (Debt 116.5m / last Quarter total Stockholder Equity 6.64b)
Debt / EBITDA = 0.13 (Net Debt -1.84b / EBITDA 888.7m)
Debt / FCF = 0.09 (Debt 116.5m / FCF TTM 1.33b)
Total Stockholder Equity = 6.05b (last 4 quarters mean)
RoA = 10.12% (Net Income 809.9m, Total Assets 8.00b )
RoE = 13.40% (Net Income TTM 809.9m / Total Stockholder Equity 6.05b)
RoCE = 14.12% (Ebit 868.9m / (Equity 6.05b + L.T.Debt 105.8m))
RoIC = 11.16% (NOPAT 674.9m / Invested Capital 6.05b)
WACC = 8.71% (E(46.35b)/V(46.47b) * Re(8.68%)) + (D(116.5m)/V(46.47b) * Rd(25.96%) * (1-Tc(0.22)))
Shares Correlation 3-Years: 96.97 | Cagr: 0.27%
Discount Rate = 8.68% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.97% ; FCFE base≈1.19b ; Y1≈1.36b ; Y5≈1.88b
Fair Price DCF = 176.1 (DCF Value 28.87b / Shares Outstanding 163.9m; 5y FCF grow 16.66% → 3.0% )
Revenue Correlation: 97.56 | Revenue CAGR: 13.85%
Rev Growth-of-Growth: 1.32
EPS Correlation: 93.94 | EPS CAGR: 22.85%
EPS Growth-of-Growth: -0.53
Additional Sources for VEEV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle